Skip to main content

DCGI orders state drug controllers to strictly control manufacture, sale & distribution of oxytocin

 

Clinical courses

The Drugs Controller General  of India (DCGI) has ordered state pharmaceutical inspectors to maintain strict regulatory control over the manufacture, sale and distribution of oxytocin and to curb its abuse by manufacturers.

The DCGI Directive follows a meeting in this respect convened by the Secretary of the Union's Ministry of Health on 14 March 2017 to review the situation concerning the limitation and regulation of the manufacture of Oxytocin and the manufacture of the feeding unit in accordance with the judgment of the High Court of Himachal Pradesh.

As regards the control of the manufacture, sale and distribution of oxytocin, it was decided at the meeting that a mechanism should be established in CDSCO to receive complaints concerning the illegal production of oxytocin and Its misuse.

 

The DCGI, in its directive, asked state drug controllers to submit details of cases where manufacturers were directed by them to stop the manufacture of oxytocin in bulk / injection in their condition and the measures taken at this subject.

The DCGI asked state drug controllers to inspect all oxytocin units in their condition within one month to verify compliance with the requirements of the 1940 Act. Drugs and cosmetics and the 1945 rules established under these units.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email